QT interval prolongation by noncardiovascular drugs: A proposed assessment strategy

Drug Development Research

Volumn 47, Issue 2, 1999, Pages 55-62

  Pourrias, Bernard ^a   Porsolt, Roger D ^b   Lacroix, Pierre ^b  

^a Ctr Europ de Bioprospective   (France)

^b Phoenix International Pharmacology   (France)

Author keywords

Cardiac risk assessment; Drug induced arrhythmia; Safety pharmacology; Torsades de pointes; Ventricular tachycardia

Indexed keywords

ACECAINIDE; AJMALINE; ALMOKALANT; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIPARASITIC AGENT; APRINDINE; BEPRIDIL; BRETYLIUM; BUTYROPHENONE DERIVATIVE; DOFETILIDE; ERYTHROMYCIN; FLECAINIDE; IBUTILIDE; IMIPRAMINE; INDECAINIDE; KETANSERIN TARTRATE; LIDOFLAZINE; MOXAPRINDINE; PHENOTHIAZINE DERIVATIVE; PRENYLAMINE; PROCAINAMIDE; PSYCHOTROPIC AGENT; QUINIDINE DERIVATIVE; SOTALOL; SULTOPRIDE; UNINDEXED DRUG;

ACTION POTENTIAL; CARDIOVASCULAR RISK; DOG; DRUG INDUCED DISEASE; DRUG SAFETY; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HUMAN; PURKINJE FIBER; QT INTERVAL; REVIEW; RISK ASSESSMENT; TELEMETRY; TORSADE DES POINTES;

EID: 0032771932     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199906)47:2<55::AID-DDR1>3.0.CO;2-3     Document Type: Review

References (51)

1. Anon. 1997. Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. Committee for Proprietary Medicinal Products (CPMP), Human Medicines Evaluation Unit, Publication No. CPMP 986 96.
2. Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M, Romey G. 1996. K(V)LQT1 and IsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature 384:78-80.
3. Bhandari AK, Quock C, Sung RJ. 1984. Polymorphous ventricular tachycardia associated with a marked prolongation of the Q-T interval induced by amiodarone. Pacing Clin Electrophysiol 7:341-345.
4. Colatsky TJ, Argentieri T. 1994. Potassium channel blockers as antiarrhythmic drugs. Drug Dev Res 33:235-249.
5. Deharo JC, Durand A, Macaluso G, Malaterre H, Le Tallec L, Panagides D, Bory M, Djiane P. 1997. Clinical electrophysiologic effects of a single high oral dose of amiodarone. Fund Clin Pharmacol 11:275-280.
6. Dessertenne F. 1966. La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Cœur Vaiss 59:263-272.
7. El-Sherif N, Zeiler RH, Craelius W, Gough WB, Henkin R. 1988. QTU prolongation and polymorphic ventricular tachyarrhythmias due to bradycardia-dependent early afterdepolarizations. After depolarizations and ventricular arrhythmias. Circ Res 63:286-305.
8. El-Sherif N, Bekheit SS, Henkin R. 1989. Quinidine-induced long QTU interval and torsade de pointes: role of bradycardia-dependent early afterdepolarizations. J Am Cell Cardiol 14:252-257.
9. Faber TS, Zehender M, Just H. 1994. Drug-induced torsade de pointes. Incidence, management and prevention. Drug Saf 11:463-476.
10. Fowler NO, McCall D, Chou TC, Holmes JC, Hanenson IB. 1976. Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol 37:223-230.
11. Franz MR, Burkhoff D, Spurgeon H, Weisfeldt ML, Lakatta EG. 1986. In vitro validation of a new cardiac catheter technique for recording monophasic action potentials. Eur Heart J 7:34-41.
12. Funck-Brentano C, Jaillon P. 1993. Rate-corrected QT interval: techniques and limitations. Am J Cardiol 72:17B-22B.
13. Funck-Brentano C, Coudray P, Planellas J, Motte G, Jaillon P. 1990. Effects of bepridil and diltiazem on ventricular repolarization in angina pectoris. Am J Cardiol 66:812-817.
14. Giardina EG, Bigger JT Jr, Glassman AH, Perel JM, Kantor SJ. 1979. The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation 60:1045-1052.
15. Hanrahan JP, Choo PW, Carlson W, Greineder D, Faich GA, Platt R. 1995. Terfenadine-associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among numbers of a health maintenance organization. Ann Epidemiol 5:201-209.
16. Hoffmann BE, Cranefield PF. 1960. Electrophysiology of the heart. New York: McGraw-Hill. p 202-219.
17. Hoffmann BF, Cranefield PF, Lepeschkin E. 1959. Confusion of cardiac monophasic action potentials recorded by intracellular and suction electrodes. Am J Physiol 196:1297.
18. Ino T, Karagueuzian HS, Hong K, Meesmann M, Mandel WJ, Peter T. 1988. Relation of monophasic action potential recorded with contact electrode to underlying transmembrane action potential properties in isolated cardiac tissues: a systematic microelectrode validation study. Cardiovasc Res 22:255-264.
19. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. 1988. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 31(2):115-172.
20. Jaillon P, Dupuis B, Dahan R. 1997. Etudes électrophysiologiques pré-cliniques et cliniques en vue de la prédiction d'un effet proarrythmique (torsades de pointes) iatrogènes. Thérapie 52:271-280.
21. Keren A, Tzivoni D, Gottlieb S, Benhorin J, Stern S. 1982. Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide. Chest 81:384-386.
22. Leclercq JF, Kural S, Valere PE. 1983. Bepridil et torsades de pointes. Arch Mal Cœur Vaiss 76:341-348.
23. Lecocq B, Lecocq V, Prost PL, Fleurot O, Boisson P, Jaillon P. 1990. Effects of bepridil and CERM 4205 (ORG 30701) on the relation between cardiac cycle length and QT duration in healthy volunteers. Am J Cardiol 66:636-641.
24. Lui HK, Lee G, Dietrich P, Low RI, Mason DT. 1982. Flecainide-induced QT prolongation and ventricular tachycardia. Am Heart J 103:567-569.
25. Morganroth J. 1993. Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms. Am J Cardiol 72:10B-13B.
26. Neuvonen PJ, Elonen E, Vuorenmaa T, Laakso M. 1981. Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication. Eur J Clin Pharmacol 20:85-90.
27. Neyroud N, Tesson F, Denjoy I, Leibovici M, Donger C, Barhanin J, Faure S, Gary F, Coumel P, Petit C, Schwartz K, Guicheney P. 1997. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet 15:186-189.
28. Olsson B, Varnauskas E, Korsgren M. 1971. Further improved method for measuring monophasic action potentials of the intact human heart. J Electrocardiol 4:19-23.
29. Olsson B, Brorson L, Varnauskas E. 1973. Class 3 antiarrhythmic action in man. Observations from monophasic action potential recordings and amiodarone treatment. Br Heart J 35:1255-1259.
30. Oravetz J, Slodki SJ. 1968. Recurrent ventricular fibrillation precipitated by quinidine. Report of a patient with recovery after 28 paroxysms. Arch Intern Med 122:63-65.
31. Platia EV, Weisfeldt ML, Franz MR. 1988. Immediate quantitation of antiarrhythmic drug effect by monophasic action potential recording in coronary artery disease. Am J Cardiol 61:1284-1287.
32. Porsolt RD. 1997. Safety pharmacology - a critical perspective. Drug Dev Res 41:51-57.
33. Pressler ML, Warner MR, Rubart M, Rardon DP, Zipes DP. 1995. In vivo and in vitro electrophysiologic effects of terodiline on dog myocardium. J Cardiovasc Electrophysiol 6:443-454.
34. Priori SG, Mantica M, Schwartz PJ. 1988. Delayed afterdepolarizations elicited in vivo by left stellate ganglion stimulation. Circulation 78:178-185.
35. Rampe D, Murawsky MK, Grau J, Lewis EW. 1998. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG1. J Pharmacol Exp Ther 286:788-793.
36. kr potassium channel. Cell 81:299-307.
37. Sato T, Hirao K, Hiejima K. 1993. The relationship between early afterdepolarization and the occurrence of torsades de pointes - an in-vivo canine model study. Jpn Circ J 57:543-552.
38. Selzer A, Wray HW. 1964. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30:17-26.
39. Steinberg MI, Greenspan K. 1976. Intracellular electrophysiological alterations in canine cardiac conducting tissue induced by aprindine and lignocaine. Cardiovasc Res 10:236-244.
40. Strasberg B, Sclarovsky S, Erdberg A, Duffy CE, Lam W, Swiryn S, Agmon J, Rosen KM. 1981. Procainamide-induced polymorphous ventricular tachycardia. Am J Cardiol 47:1309-1314.
41. Stroobandt R, Brachmann J, Kesteloot H, Kubler W, Senges J. 1986. Effect of sotalol, aprindine and the combination aprindine-sotalol on monophasic action potential duration. Eur Heart J 7:47-53.
42. Sullivan AT. 1994. Present testing strategy. An industry view. Proceedings of workshop on use of pharmacology studies in drug safety assessments. Present situation and future perspectives. Stockholm, p 3-8.
43. Sullivan AT, Kinter LB. 1995. Status of safety pharmacology in the pharmaceutical industry - 1995. Drug Dev Res 35:166-172.
44. Surawicz B, Knoebel SB. 1984. Long QT: good, bad or indifferent? J Am Coll Cardiol 4:398-413.
45. Thomas SH. 1994. Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Drug React Toxicol Rev 13:77-102.
46. Thomas M, Maconochie JG, Fletcher E. 1996. The dilemma of the prolonged QT interval in early drug studies. Br J Clin Pharmacol 41:77-81.
47. Thompson D, Oster G. 1996. Use of terfenadine and contraindicated drugs. JAMA 275:1339-1341.
48. Tzivoni D, Keren A, Stern S, Gottlieb S. 1981. Disopyramide-induced torsade de pointes. Arch Intern Med 141:946-947.
49. van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB. 1996. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 124:168-175.
50. Verdonck F, Vereecke J, Vleugels A. 1974. Electrophysiological effects of aprindine on isolated heart preparations. Eur J Pharmacol 26:338-347.
51. r. Implications for torsade de pointes and reverse use-dependence. Circulation 93:407-411.